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Abstract: Fetal growth in utero depends on the proper development and func-
tion of the placenta. Insulin-like growth factors (IGFs) are critically involved in 
placental development. During pregnancy, an IGF-binding protein, IGFBP-1, 
which is produced by maternal decidua, plays an important role in the control 
of the bioavailability of IGFs. It has recently been proposed that cleavage of 
decidual IGFBP-1 by matrix metalloproteases is a novel mechanism in the con-
trol of placental development. The presence of IGFBP-1 in solubilized placen-
tal cell membranes, i.e. its association with the membranes, was detected in an 
earlier work. Herein, it is shown that IGFBP-1 from the solubilized membranes 
forms dimers, as well as high molecular mass complexes. IGFBP-1 dimers pre-
ferably contain the non-phosphorylated form of IGFBP-1. The high molecular 
mass forms are polymers of IGFBP-1 or its complexes with other membrane 
proteins. Dimerization of IGFBP-1, together with its association with the pla-
cental cell membrane, could serve as an additional mechanism of the regulation 
of IGF availability to the type 1 IGF receptors. 
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INTRODUCTION 
The insulin-like growth factor (IGF) axis is an important regulator of fetal 
growth and it has been suggested that IGF-I and -II may, in part, mediate this 
effect by promoting proper placental development and function.1 For IGFs to 
exert their effects, they must interact with cell-surface receptors, principally the 
type 1 IGF receptor (IGF1R).2 IGF-II can also bind to the type 2 IGF receptor 
(IGF2R) and insulin receptor isoform A (IR-A).2 Ligand access to these recep-
tors is controlled by a family of six IGF binding proteins (IGFBPs 1–6).2,3 
IGFBPs have similar or higher affinities for IGFs than IGF1R, suggesting that 
the formation of IGF–IGFBP complexes is favored over the formation of IGF– 
–IGF1R complexes. Acting through this mechanism, IGFBPs would sequester 
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IGFs and act as inhibitors of IGF actions.4 In certain physiological situations, 
IGFBPs can enhance biological actions of IGFs, which was shown for IGFBP-3.3 
However, there are many physiological situations (e.g., pregnancy), in which 
IGFs must be released from IGFBPs, principally through decreasing their affi-
nities for IGFs. This could be realized by the binding of IGFBPs to extracellular 
matrix components or by post-translational modifications of IGFBPs.4 
Immunohistochemical studies showed IGFBP-2 in the syncityotrophoblast 
cells of the placenta.5 IGFBP-1 and IGFBP-3 are produced in abundance by the 
maternal–fetal interface.5 IGFBP-1 was found to associate with the membrane of 
placental trophoblast cells.6 It is thought that IGFBP-1 regulates the biological 
activity of IGFs within the local environment of the human placenta by modu-
lating their interaction with the IGF1R.7 The role of IGFBP-1 in the placenta is 
not yet elucidated and the mechanisms involved are under vigorous research. 
Post-translational modifications, including phosphorylation,8 proteolysis,9 and 
polymerization,10 have been shown to alter the affinity of IGFBP-1 for IGF-I. 
Three phosphorylation sites have been identified in human IGFBP-1: Ser 101, 
119 and 169.11 When human IGFBP-1 purified from amniotic fluid or a cell cul-
ture supernatant is analyzed by non-denaturing gel electrophoresis, one non-phos-
phorylated (np-IGFBP-1) and four phosphorylated isoforms (p-IGFBP-1) can be 
identified.12 In the circulation of non-pregnant women, IGFBP-1 almost exclusi-
vely exists as p-IGFBP-1, which has high affinity for IGFs. During pregnancy, 
however, IGFBP-1 becomes dephosphorylated by placental alkaline phosphatase 
to np-IGFBP-1 and lesser phosphorylated isoforms, which have a reduced affi-
nity for IGF-I. Whereas p-IGFBP-1 is inhibitory, np-IGFBP-1 stimulates the ac-
tion of IGF-I.8 
Sakai and co-workers10 demonstrated the formation of covalently linked mul-
timers of IGFBP-1 by a tissue transglutaminase in vitro, as well as by a fibroblast 
membrane extract. They also detected the polymerized forms of IGFBP-1 in hu-
man amniotic fluid. These findings prompted the herein described examination of 
the association/polymerization of the IGFBP-1 protein associated with placental 
cell membranes. 
EXPERIMENTAL 
Materials 
Na125I was supplied by Isotope (Budapest, Hungary). Human IGF-I and des(1–3)IGF-I 
(IGF-I lacking the three amino acid residues at the N-terminus) were from GroPep (Adelaide, 
Australia). Affinity purified goat polyclonal anti-human IGFBP-1 antibodies were from DSL 
(Webster, USA). Horse radish peroxidase-conjugated (HRP) anti-goat IgG was supplied by 
Biosource (Camarillo, USA). Enhanced chemiluminescence (ECL) detection reagents were 
the products of Amersham Biosciences (Aylesbury, UK) and MXB films and developing re-
agents were from Kodak (Paris, France). All other chemicals were purchased from Sigma-Al-
drich (Steinheim, Germany). 125I–IGF-I and 125I–des(1–3)IGF-I were prepared using the 
chloramine T method.13 
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Human placental tissue was obtained from uncomplicated pregnancies at term, according 
to protocols approved by the local ethical committee. The tissue was collected in ice cold 0.10 
M phosphate buffered saline (pH 7.4) and brought to laboratory within 60 min. After washing 
the placenta free of blood, the amniotic and chorionic membranes were dissected away. The 
placental tissue was minced and homogenized in a 0.25 M sucrose solution with protease inhi-
bitors. After a short centrifugation to remove the cell debris, the supernatant was centrifuged 
at 18000 x g for 30 min. The pellet was resuspended and solubilized by Triton X-100. The 
solubilized membranes were recovered in the supernatant after centrifugation at 100,000 x g 
for 90 min. The detailed procedure was described in a previous article.14 
Gel filtration 
Solubilized membranes (2 mg of membrane protein) were incubated with 125I–IGF-I or 
125I–des(1–3)IGF-I (1 pmol, 106 cpm) at 4 °C overnight. In some cases, the solubilized mem-
branes were incubated with the tracers in the presence of high concentrations of unlabeled 
IGF-I or des(1–3)IGF-I (4 μg). The samples were then subjected to gel filtration on a Sepha-
dex G-100 column, exactly as described previously.15 In some cases, the solubilized membra-
nes (45 mg of membrane proteins) were applied on the column without prior incubation with 
the tracer and the collected fractions were employed in electrophoresis and in binding assays 
with 125I-labeled IGF-I and des(1–3)IGF-I. In a separate experiment, fractions from 9 to 15 
were pooled and the pool was designated as peak 1 proteins. The binding assays commenced 
by incubating aliquots (50 μL) of the fractions obtained after gel filtration with 125I–IGF-I or 
125I–des(1–3)IGF-I (105 cpm) and were performed as described earlier.16 The protein concen-
trations were determined using the Bradford protein assay17 with ovalbumin standards. 
Gel electrophoresis and blotting 
Aliquots of the fractions obtained from gel filtration were subjected to both non-reducing 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS PAGE, in 8 % gel) and to 
non-denaturing PAGE (in 10 % gel). The samples were mixed with an equal volume of sam-
ple buffer (0.125 M Tris-HCl, 4 % SDS, 20 % glycerol, 0.010 % bromphenol blue, pH 6.8) 
and boiled for 7 min before being applied onto the gels. The non-denaturing PAGE was per-
formed following the procedure for SDS PAGE,18 except that the SDS was omitted from all 
the buffers, including the sample buffer. The proteins were transferred to Immobilon P mem-
branes (Millipore, Billerica, USA) and probed with anti-human IGFBP-1 antibodies as des-
cribed previously.18 The immunoreactive proteins were visualized using HRP-conjugated anti- 
-goat IgG antibodies and an ECL detection system, followed by autoradiography. Before the 
ligand blotting, the solubilized membranes and peak 1 proteins were subjected to SDS PAGE 
using an 8 % gel and then the membranes were probed with 125I–IGF-I (2.5×106 cpm in 50 
mL of 0.010 M Tris-HCl, 0.15 M NaCl, pH 7.4) and visualized by autoradiography as des-
cribed previously.19 
Immunoradiometric assay (IRMA) of IGFBP-1 
The IGFBP-1 concentration in the fractions eluted from the Sephadex G-100 column was 
determined by a DSL (Webster, USA) Total IGFBP-1 IRMA kit. 
RESULTS AND DISCUSSION 
The proteins which interacted with 125I–IGF-I and with 125I–des(1–3)IGF-I 
were detected after separation by gel filtration of the solubilized placental cell 
membranes pre-incubated with the tracers (Fig. 1). The first peak (peak 1), which 
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appears at the void volume (V0) of the column, is known to contain complexes of 
IGF1R with 125I-labeled IGF-I or des(1–3)IGF-I, whereas the second peak con-
tains 125I–IGF-I/IGFBP-1 complexes.15 Peak 2 is missing in the elution profile 
of the solubilized membranes pre-incubated with 125I–des(1–3)IGF-I, because it 
has a markedly reduced affinity for IGFBPs.20 Peak 3 represents unbound 125I- 
-labeled ligand. 
 
Fig. 1. Two identical samples of solubilized membranes (2 mg of total membrane protein) 
were incubated with 1×106 cpm of 125I–IGF-I (full circles) and 125I–des(1–3)IGF-I (empty 
circles) before being applied to a Sephadex G-100 column ((1.8×60) cm) and eluted using 
0.050 M sodium phosphate buffer, pH 7.5, containing 0.10 M NaCl and 0.10 % Triton X-100. 
The flow rate was 20 mL/h. Following the pre-elution of 20 mL, 2 mL fractions were 
collected and the radioactivity in each was measured. The positions of molecular mass 
markers (Tg-thyroglobulin, OA-ovalbumin) are indicated. The results from 
representative experiments are illustrated. 
The specificity of ligand binding to peak 1 and peak 2 proteins was analyzed 
by gel-filtration of the solubilized membranes, which were pre-incubated with 
125I-labeled ligands in the presence of high concentrations of unlabeled ligands. 
The 125I–des(1–3)IGF-I binding in peak 1 was specific, as this peak disappeared 
upon gel filtration in the presence of 4 μg of either unlabeled IGF-I or des(1– 
–3)IGF-I (results not shown). This pattern of cross-reactivity reflects the fact that 
des(1–3)IGF-I binds to IGF1R with a similar affinity to the full length IGF-I.21 
In contrast, 125I–IGF-I bound to the proteins in peak 1 could not be completely 
displaced by unlabeled des(1–3)IGF-I, whereas unlabeled IGF-I reduced the bind-
ing of the ligand to the level of non-specific binding (Fig. 2). In other words, a 
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proportion of 125I–IGF-I binds to the protein(s) of peak 1 to which des(1–3)IGF-I 
does not bind. 
 
Fig. 2. Solubilized membranes (2 mg of total membrane protein) were incubated with 1×106 
cpm of 125I–IGF-I, without competing ligand (full circles) or in the presence of unlabeled 
competitor: IGF-I (empty circles), des(1–3)IGF-I (asterisks), applied to a Sephadex G-100 
column and eluted as described (see legend under Fig. 1). 
To investigate whether IGFBP-1 was also present among the proteins of high 
molecular mass in peak 1, the concentration of IGFBP-1 in the fractions eluted 
after chromatography of 45 mg of solubilized membrane proteins was measured 
immunoradiometrically. The results are shown in parallel with the graph that 
represents the binding of 125I–IGF-I in fractions eluted after the preparative gel 
filtration (Fig. 3). The highest IGFBP-1 concentrations, according to the DSL To-
tal IGFBP-1 IRMA, were detected in fractions 24–28, with the maximal value in 
fraction 26 (above 230 ng/mL), coinciding with peak 2. Fractions that belonged to 
peak 1 also contained IGFBP-1. In other words, IGFBP-1 eluted within V0, among 
the other high molecular mass proteins, such as IGF1Rs, IGF2Rs and IRs.14 
To examine the possibility that IGFBP-1 from placental cell membranes 
existed in the form of a high molecular mass species, the fractions of peak 1 and 
peak 2 were analyzed by SDS PAGE, followed by immunoblotting using affinity 
purified polyclonal anti-human IGFBP-1 antibodies (Fig. 4). Several molecular 
forms of IGFBP-1 from the solubilized placental cell membranes were visible on 
the immunoblots (Fig. 4). The 60 kD-band on the blot in Fig. 4 most probably 
originated from dimeric IGFBP-1, which peaked in fractions 18 to 21. The exis-
tence of covalently linked monomers of IGFBP-1, which formed dimers follow-
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ing exposure to pure tissue transglutaminase, was reported.10 Monomeric IGFBP-1 
(molecular mass of 29 kD) bands were seen at the bottom of the gel, with the 
greatest abundance in fractions eluting after fraction 21. Some of these fractions 
also showed the greatest IGFBP-1 concentration in IRMA (Fig. 3). However, the 
concentration of IGFBP-1 in the fractions in which IGFBP-1 was present mostly 
as a dimer was low. In other words, the antibodies used in IRMA poorly reco-
gnized the dimeric IGFBP-1 forms. According to the immunoblot in Fig. 4, high 
molecular mass proteins (of approximately 150 and 220 kD) that were immuno-
reactive with anti-IGFBP-1 antibodies were also detected (gel filtration fractions 
12 to 15). These proteins are either polymers of IGFBP-1 or its complexes with 
other proteins from placental cell membranes. 
 
Fig. 3. Solubilized membranes (45 mg of total membrane protein) were chromatographed on a 
Sephadex G-100 column as usual, but without pre-incubation with 125I–IGF-I. The binding of 
125I–IGF-I in each fraction was measured by ligand binding assay. The result from a repre-
sentative experiment is illustrated. The concentration of IGFBP-1 in the fractions, 
measured by DSL Total IGFBP-1 IRMA, is shown in parallel (ng/mL). 
 
Fig. 4. The fractions eluted from the Sephadex G-100 column were analyzed by SDS PAGE 
(8 % gels) followed by immunoblotting using affinity purified goat polyclonal anti-human 
IGFBP-1 antibodies. The blots are of two gels that were run simultaneously in one 
electrophoretic unit. Molecular mass markers (in kD) are shown on the left. 
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A further step was to check whether np-IGFBP-1 and p-IGFBP-1 were diffe-
rently distributed between the peak 1 and peak 2 proteins. Non-denaturing PAGE 
followed by immunoblotting for IGFBP-1 was undertaken to analyze the phos-
phoisoform pattern of IGFBP-1 in the fractions eluted after gel filtration (Fig. 5). 
The results presented in Fig. 5 clearly show that the fractions contained different 
isoforms of IGFBP-1. The band positions of p- and np-IGFBP-1 isoforms upon 
non-denaturing PAGE were established knowing that the phosphorylated forms, 
due to their charge density, migrate towards the anode faster than the np-IGFBP- 
-1.22 The same pattern of bands was obtained by others upon non-reducing 
PAGE of IGFBP-1 from human amniotic fluid.22,23 np-IGFBP-1 was mostly pre-
sent in fractions number 18 to 21, which were the same fractions that contained 
the dimeric form of IGFBP-1 (see Fig. 4). These results strongly suggest that the 
dimeric form of IGFBP-1, associated with the placental cell membranes, consists 
almost exclusively of the np-IGFBP-1 isoform. These findings are in accordance 
with those obtained by others, who observed that np-IGFBP-1 polymerized more 
rapidly and to a greater extent than phosphorylated isoforms.10 Monomeric 
IGFBP-1, however, mostly contained phosphorylated isoforms of IGFBP-1 (frac-
tions 24 to 28). Fraction 26, which had the greatest amount of IGFBP-1 in IRMA 
and which bound the most 125I-labeled IGF-I when pre-incubated with the tracer 
(see Fig. 1), showed the strongest bands on the immunoblots following non-dena-
turing electrophoresis. 
 
Fig. 5. The fractions eluted from the Sephadex G-100 column were applied to two 10 % gels, 
which were simultaneously subjected to non-denaturing PAGE, and then to immunoblotting 
for IGFBP-1. The upper arrow denotes the position of np-IGFBP-1. The two lower arrows 
indicate the positions of the phosphorylated isoforms of IGFBP-1. 
The ligand binding properties of IGFBP-1 forms were also examined in this 
study. The affinity of IGFBP-1 isoforms present in the solubilized placental 
membranes and in peak 1 for 125I-labeled IGF-I was assessed using ligand blot. 
As can be seen in Fig. 6, the monomeric IGFBP-1 was the only protein able to 
bind 125I–IGF-I, giving a strong single band. The binding of 125I-labeled IGF-I to 
the IGFBP-1 dimer or to some other high molecular mass proteins could not be 
demonstrated. The binding of the tracer to IGF1R was also lacking. It is gene-
rally believed that polymeric forms of IGFBP-1 do not bind the ligand,10 but 
some of the present results indicate that a proportion of 125I–IGF-I bound to the 
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protein(s) of peak 1 to which des(1–3)IGF-I did not bind, most probably IGFBP-1. 
Although the ligand blot result suggests the monomeric form of IGFBP-1 as the 
sole molecular species able to bind the ligand, the technique might not be as sen-
sitive as gel filtration of the pre-labeled placental membrane proteins. 
Fig. 6. The solubilized placental membrane pro-
teins and proteins eluted in peak 1 after gel filtra-
tion on Sephadex G-100 were analyzed by 8 % 
SDS PAGE followed by ligand blotting using 125I–
–IGF-I. Lanes 1 and 2 contained solubilized mem-
branes and lanes 3 and 4, peak 1 proteins (pooled 
fractions 9 to 15 from preparative gel filtration). 
Molecular mass markers (in kD) are shown on the 
left. The arrow denotes the position of monomeric 
IGFBP-1. 
These results are in accordance with those presented in Fig. 1, where frac-
tions containing dimers of IGFBP-1 resided between peaks 1 and 2. These re-
sults, however, may be taken into account in the light of the finding of others 
who demonstrated that the formation of multimers of IGFBP-1 led to a reduction 
or loss of IGF-I binding.10 Since the ability of IGFBP-1 to polymerize was also 
shown to be related to the loss of its capacity to inhibit IGF-I actions, it was sug-
gested that this may be one mechanism by which phosphorylation of IGFBP-1 
may enhance its inhibitory potential.10 The deletion of twenty C-terminal amino 
acids from the IGFBP-1 molecule was also reported to result in a loss of IGF bin-
ding and the formation of
 dimeric IGFBP-1 molecules.24 
Tissue transglutaminase is an enzyme which is widely distributed in many 
tissues and organs and which has been localized to the cytoplasm,25 cell sur-
face26 and extracellular matrix.27 Polymerization of IGFBP-1 is catalyzed not 
only by the isolated enzyme, but also by fetal fibroblast cell cultures and their 
membrane extract.10 The expression of tissue transglutaminase at the embryo-ma-
ternal interface was recently discovered,28 hence, this enzyme might be respon-
sible for the presence of the IGFBP-1 dimers detected in this study. 
Relevant literature data were sought in order to find protein candidates that 
might associate with the IGFBP-1 in the placental cell membranes. In human 
plasma, α2-macroglobulin (α2-M) forms high molecular mass complexes with 
IGFBP-1, it preferentially associates with p-IGFBP-1 and these complexes can 
still bind IGF-I.29 On the other hand, the high molecular mass complexes of 
IGFBP-1 detected in this study consisted almost exclusively of np-IGFBP-1. Fur-
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thermore, these forms bound only small amounts of 125I-labeled IGF-I. α2-M was 
detected in placental trophoblast.30 It is known that some anti-IGFBP-1 anti-
bodies recognize IGFBP-1 even when it is engaged in a complex with α2-M, but 
some cannot.29 The association of IGFBP-1 with α2-M is suggested to be of low 
affinity, resulting in the dissociation of the complex during gel filtration,29 
whereas the high molecular mass complexes of IGFBP-1, which were immune-
detected in the present experiments, survived the 7-min heating with SDS prior to 
SDS PAGE. An association of IGFBP-1 with α2-M still cannot be ruled out. 
When the phosphoisoforms of IGFBP-1 were separated by anion exchange 
chromatography, the fractions that contained phosphorylated forms inhibited 
IGF-I actions, whereas those that were enriched in np-IGFBP-1, potentiated IGF-I 
actions.22 Taking this into account, it can be presumed that phosphorylation is 
the major factor modulating the affinity of IGFBP-1 for IGFs. It is suggested that 
the generation of non-phosphorylated and phosphorylated isoforms of IGFBP-1 
and their association with cell membranes are involved in the regulation of IGF 
availability to IGF1R. Dimerization of IGFBP-1 may be a reversible process, ca-
talyzed by membrane-associated tissue transglutaminase. Since IGFBP-1 and 
IGF1R compete for the ligand, increased binding of IGF-I to the IGF1R could be 
achieved through increased sequestering of high-affinity p-IGFBP-1 in dimers. 
The biological significance of dimeric IGFBP-1 forms has yet to be revealed. 
CONCLUSIONS 
Previously, the presence of IGFBP-1 in solubilized placental cell membranes 
was detected, i.e. its association with the membranes. Herein, it is reported that 
IGFBP-1 forms dimers, which preferably contain np-IGFBP-1. Polymerization of 
IGFBP-1 in vitro can be catalyzed by tissue transglutaminase, which was recently 
detected at the embryo-maternal interface. This enzyme might be responsible for 
the presence of the IGFBP-1 dimers detected in this study. 
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ИЗВОД 
ФОРМЕ ИГФБП-1 У МЕМБРАНАМА ПЛАЦЕНТНИХ ЋЕЛИЈА 
РОМАНА МАСНИКОСА, БОГОВИД ЖИВКОВИЋ и ОЛГИЦА НЕДИЋ 
INEP–Institut za primenu nuklearne energije, Banatska 31b, 11080 Beograd 
Унутарматерични раст фетуса зависи oд правилног развоja и ваљаног функционисањa 
плацентe. Инсулину-слични фактори растa (IGF) су важни фактори зa развoj плацентe. Зa 
времe гестациje, измењени ендометријум материце (децидуa) синтетишe IGF-везујући про-
теин-1 (IGFBP-1), који  контролише  биолошко  дејство IGF молекула.  Разградња IGFBP-1 
пореклом из децидуе, дејством металопротеаза из матрикса, сматра се новим механизмом 
контроле  развића  плаценте.  У  нашем  ранијем  раду  утврдили  смо  присуство IGFBP-1 у 
солубилизованим мембранама ћелија из плаценте, што смо објаснили везивањем IGFBP-1 за 
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ћелијске  мембране.  У  овом  раду  показано  је  да IGFBP-1 из  солубилизованих  мембрана 
образује димере, као и комплексе великих молекулских маса. Димери IGFBP-1 претежно 
садрже нефосфориловане молекуле мономерног IGFBP-1, док облици IGFBP-1 великих мо-
лекулских  маса  представљају  агрегате IGFBP-1, и/или  његове  комплексе  са  другим  мем-
бранским протеинима. Димеризација IGFBP-1, као и његова асоцијација са ћелијским мем-
бранама из плаценте, могла би да представља додатни механизам за регулацију доступности 
IGF молекула за тип 1 IGF рецепторa. 
(Примљено 9. марта, ревидирано 7. априла 2009) 
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